Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Negócios · 15/04/20041 min de leitura
Referral of ZONEGRAN (Zonisamide), WELLBUTRIN and ZYBAN (Bupropion), and RENAGEL (Sevelamer) for the Conduct of Pediatric Studies
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA) is announcing the referral of ZONEGRAN (zonisamide), WELLBUTRIN and ZYBAN (bupropion), and RENAGEL (sevelamer) to the Foundation for the National Institutes of Health (the Foundation) for the conduct of pediatric studies. FDA referred these drugs to the Foundation on November 14, 2003, and is publishing this notice of the referrals.
Idioma original da fonte: Federal Register — Food and Drug AdministrationAbrir o comunicado original →